Syneos Health, Inc. (SYNH)
Stock Price Chart
Key Info
| Market Cap | 5.55B |
| Revenue (ttm) | 4.49B |
| Net Income (ttm) | 191.95M |
| Shares Out | 104.00M |
| EPS (ttm) | 1.83 |
| PE Ratio | 29.01 |
| Forward PE | 15.38 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 30, 2020 |
| Last Price | $53.08 |
| Previous Close | $54.14 |
| Change ($) | -1.06 |
| Change (%) | -1.96% |
| Day's Open | 54.29 |
| Day's Range | 52.29 - 55.93 |
| Day's Volume | 879,100 |
| 52-Week Range | 30.02 - 74.25 |
More Stats
| Market Cap | 5.55B |
| Enterprise Value | 8.11B |
| Earnings Date (est) | Mar 3, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 104.00M |
| Float | 69.07M |
| EPS (basic) | 1.85 |
| EPS (diluted) | 1.83 |
| FCF / Share | 4.03 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 3.45% |
| FCF Yield | 7.57% |
| Payout Ratio | n/a |
| Shares Short | 5.74M |
| Short Ratio | 5.14 |
| Short % of Float | 8.30% |
| Beta | 1.74 |
| PE Ratio | 29.01 |
| Forward PE | 15.38 |
| P/FCF Ratio | 13.21 |
| PS Ratio | 1.24 |
| PB Ratio | 1.85 |
| Revenue | 4.49B |
| Operating Income | 241.89M |
| Net Income | 191.95M |
| Free Cash Flow | 419.89M |
| Net Cash | -2.57B |
| Net Cash / Share | -24.58 |
| Gross Margin | 22.94% |
| Operating Margin | 5.39% |
| Profit Margin | 4.30% |
| FCF Margin | 9.35% |
| ROA | 2.85% |
| ROE | 6.44% |
| ROIC | 6.70% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,676 | 4,390 | 2,672 | 1,611 | 1,399 | 1,179 | 995 | 869 | 656 |
| Revenue Growth | 6.51% | 64.3% | 65.91% | 15.11% | 18.7% | 18.46% | 14.56% | 32.41% | - |
| Gross Profit | 1,030 | 956 | 621 | 404 | 372 | 295 | 220 | 190 | 157 |
| Operating Income | 214 | 188 | -48.71 | 146 | 152 | 63.64 | 31.46 | -37.53 | -40.20 |
| Net Income | 131 | 24.28 | -138 | 113 | 117 | -23.47 | -41.53 | -59.11 | -59.55 |
| Shares Outstanding | 104 | 103 | 74.91 | 54.03 | 57.89 | 53.30 | 52.01 | 52.20 | 43.88 |
| Earnings Per Share | 1.25 | 0.23 | -1.85 | 2.03 | 1.95 | -0.51 | -0.81 | -1.14 | -1.46 |
| EPS Growth | 443.48% | - | - | 4.1% | - | - | - | - | - |
| Operating Cash Flow | 318 | 303 | 198 | 109 | 205 | 131 | 37.27 | 43.00 | -18.53 |
| Capital Expenditures | -63.97 | -54.60 | -43.90 | -31.35 | -21.11 | -25.55 | -17.71 | -9.59 | -4.76 |
| Free Cash Flow | 255 | 249 | 154 | 78.14 | 184 | 106 | 19.56 | 33.41 | -23.30 |
| Cash & Equivalents | 164 | 156 | 322 | 103 | 85.46 | 127 | 97.54 | 82.41 | - |
| Total Debt | 2,920 | 2,828 | 3,008 | 498 | 502 | 416 | 594 | 594 | - |
| Net Cash / Debt | -2,756 | -2,672 | -2,686 | -395 | -416 | -289 | -497 | -512 | - |
| Assets | 7,454 | 7,255 | 7,286 | 1,289 | 1,211 | 1,241 | 1,233 | 1,258 | - |
| Liabilities | 4,424 | 4,399 | 4,263 | 987 | 994 | 849 | 957 | 941 | - |
| Book Value | 3,030 | 2,856 | 3,023 | 301 | 217 | 392 | 276 | 317 | - |
Company Profile
Company Details
| Full Name | Syneos Health, Inc. |
| Country | United States |
| Employees | 24,000 |
| CEO | Alistair John Macdonald |
Stock Information
| Ticker Symbol | SYNH |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: SYNH |
| IPO Date | November 7, 2014 |
Description
Syneos Health operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.